Terms: = Uterine cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID
142 results:
1. Predicting Response to Immunotargeted Therapy in Endometrial cancer via Tumor Immune Microenvironment: A Multicenter, Observational Study.
Maltseva A; Kalinchuk A; Chernorubashkina N; Sisakyan V; Lots I; Gofman A; Anzhiganova Y; Martynova E; Zukov R; Aleksandrova E; Kolomiets L; Tashireva L
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612743
[TBL] [Abstract] [Full Text] [Related]
2. Atlas of Tumor and Tumor Microenvironment Cells of Lymphovascular Space Invasion (LVSI) in High-Grade Serous Endometrial Adenocarcinoma: A Case Study.
Sulaiman R; Dale A; Lin X; Aske JC; Gaster K; Starks D; Espaillat LR; De P; Dey N
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542414
[TBL] [Abstract] [Full Text] [Related]
3.
Zou Q; Wu Y; Zhang S; Li S; Li S; Su Y; Zhang L; Li Q; Zou H; Zhang X; Wang T; Liang S; Yang J; Li C
Virulence; 2024 Dec; 15(1):2319962. PubMed ID: 38380669
[TBL] [Abstract] [Full Text] [Related]
4. IL-10
Yang C; Zhang Y; Wang R; Cheng B; Wu Y; Fu X
Autoimmunity; 2024 Dec; 57(1):2290909. PubMed ID: 38084896
[TBL] [Abstract] [Full Text] [Related]
5. Regulatory T cell frequency in peripheral blood of women with advanced cervical cancer including women living with HIV.
Chetty-Sebastian D; Assounga AG
BMC Cancer; 2023 Sep; 23(1):830. PubMed ID: 37670247
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic Impact of Tumor-Infiltrating Lymphocytes, Tertiary Lymphoid Structures, and Neutrophil-to-Lymphocyte Ratio in Pulmonary Metastases from uterine Leiomyosarcoma.
Matsuda N; Yamamoto H; Habu T; Iwata K; Matsubara K; Tanaka S; Hashimoto K; Shien K; Suzawa K; Miyoshi K; Toji T; Okazaki M; Sugimoto S; Takahashi K; Toyooka S
Ann Surg Oncol; 2023 Dec; 30(13):8727-8734. PubMed ID: 37658268
[TBL] [Abstract] [Full Text] [Related]
7. Brachytherapy for targeting the immune system in cervical cancer patients.
Linares I; Berenguer Frances MÁ; Cañas R; Najjari D; Gutiérrez C; Marín S; Comas S; Guedea F; Pujol M
BMC Immunol; 2023 Aug; 24(1):23. PubMed ID: 37559025
[TBL] [Abstract] [Full Text] [Related]
8. Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial.
Rodrigues M; Vanoni G; Loap P; Dubot C; Timperi E; Minsat M; Bazire L; Durdux C; Fourchotte V; Laas E; Pouget N; Castel-Ajgal Z; Marret G; Lesage L; Meseure D; Vincent-Salomon A; Lecompte L; Servant N; Vacher S; Bieche I; Malhaire C; Huchet V; Champion L; Kamal M; Amigorena S; Lantz O; Chevrier M; Romano E
Nat Commun; 2023 Jun; 14(1):3698. PubMed ID: 37349318
[TBL] [Abstract] [Full Text] [Related]
9. Infection pattern and immunological characteristics of Epstein-Barr virus latent infection in cervical squamous cell carcinoma.
Zuo Y; Xiao H; Lv D; Huang M; Wang L; Liu J; Zhang K; Shen J; Wang Z; Wu Q; Xu Y
J Med Virol; 2023 Apr; 95(4):e28717. PubMed ID: 37184049
[TBL] [Abstract] [Full Text] [Related]
10. Contribution of HLA-G and foxp3 genes and proteins in the severity of cervical intraepithelial neoplasia during HPV infection.
da Silva NCH; Sonon P; Medeiros FS; da Silva MC; Dos Santos Gomes FO; Peixoto CA; Crispim JCO; Paiva LA; Rygaard MCV; Menezes MLB; Welkovic S; Donadi EA; Lucena-Silva N
Hum Immunol; 2023 Aug; 84(8):408-417. PubMed ID: 37149423
[TBL] [Abstract] [Full Text] [Related]
11. Tumor Microenvironment CD8 T and Treg Cells-related Genes Signature Distinguishes Distinct Prognosis and Targeted Therapies Response in Endometrial cancer.
Liu X; Feng D; Wang W; Liang J; Yu H; Ling B
J Immunother; 2023 Jun; 46(5):178-191. PubMed ID: 37098928
[TBL] [Abstract] [Full Text] [Related]
12. Mesenchymal Stem/Stromal Cells Derived from Cervical cancer Promote M2 Macrophage Polarization.
Cortés-Morales VA; Chávez-Sánchez L; Rocha-Zavaleta L; Espíndola-Garibay S; Monroy-García A; Castro-Manrreza ME; Fajardo-Orduña GR; Apresa-García T; Gutiérrez-de la Barrera M; Mayani H; Montesinos JJ
Cells; 2023 Mar; 12(7):. PubMed ID: 37048119
[TBL] [Abstract] [Full Text] [Related]
13. Increase of the T-reg-recruiting chemokine CCL22 expression in a progressive course of cervical dysplasia.
Vattai A; Kremer N; Meister S; Beyer S; Keilmann L; Buschmann C; Corradini S; Schmoeckel E; Kessler M; Mahner S; Jeschke U; Hertlein L; Kolben T
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6613-6623. PubMed ID: 36792811
[TBL] [Abstract] [Full Text] [Related]
14. Integrated single-cell transcriptome analysis of the tumor ecosystems underlying cervical cancer metastasis.
Li C; Liu D; Yang S; Hua K
Front Immunol; 2022; 13():966291. PubMed ID: 36569924
[TBL] [Abstract] [Full Text] [Related]
15. Efficacy and Synergy with Cisplatin of an Adenovirus Vectored Therapeutic E1E2E6E7 Vaccine against HPV Genome-Positive C3 cancers in Mice.
Boilesen DR; Neckermann P; Willert T; Müller MD; Schrödel S; Pertl C; Thirion C; Asbach B; Wagner R; Holst PJ
Cancer Immunol Res; 2023 Feb; 11(2):261-275. PubMed ID: 36534088
[TBL] [Abstract] [Full Text] [Related]
16. Predictive value of an exosomal microRNA-based signature for tumor immunity in cervical cancer patients treated with chemoradiotherapy.
Someya M; Hasegawa T; Tsuchiya T; Kitagawa M; Fukushima Y; Gocho T; Mafune S; Ikeuchi Y; Kozuka Y; Idogawa M; Hirohashi Y; Torigoe T; Iwasaki M; Matsuura M; Saito T; Sakata KI
Med Mol Morphol; 2023 Mar; 56(1):38-45. PubMed ID: 36367588
[TBL] [Abstract] [Full Text] [Related]
17. VALIDATION OF A PANEL OF BIOMARKERS ASSOCIATED WITH AGGRESSIVE PHENOTYPE OF ENDOMETRIOID CARCINOMA OF ENDOMETRIUM.
Buchynska LG; Iurchenko NP; Nesina IP; Glushchenko NM
Exp Oncol; 2022 Nov; 44(3):234-238. PubMed ID: 36325701
[TBL] [Abstract] [Full Text] [Related]
18. The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.
López-Janeiro Á; Villalba-Esparza M; Brizzi ME; Jiménez-Sánchez D; Ruz-Caracuel I; Kadioglu E; Masetto I; Goubert V; Garcia-Ros D; Melero I; Peláez-García A; Hardisson D; de Andrea CE
J Pathol; 2022 Dec; 258(4):426-436. PubMed ID: 36169332
[TBL] [Abstract] [Full Text] [Related]
19. T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating foxp3 transcription in cervical cancer.
Ni H; Zhang H; Li L; Huang H; Guo H; Zhang L; Li C; Xu JX; Nie CP; Li K; Zhang X; Xia X; Li J
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36126994
[TBL] [Abstract] [Full Text] [Related]
20. Multiparametric immune profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: an exploratory study of the CLAP trial.
Wang Y; Lai Y; Peng H; Yan S; Liu Z; Tong C; Huang X
Clin Transl Oncol; 2023 Jan; 25(1):256-268. PubMed ID: 36115931
[TBL] [Abstract] [Full Text] [Related]
[Next]
